Elanco reports pet parasite treatment quickly hit $100M blockbuster status

Greenfield-based Elanco Animal Health announced Monday that its medicine targeting six common pet parasites reached $100 million in sales in just eight months, the company’s fastest pet-health blockbuster.

Credelio Quattro is a chewable tablet that protects dogs from fleas, ticks, heartworm disease, and three risky intestinal parasites: roundworms, hookworms and tapeworms. The medicine, launched in January, by June had gained 14% of market share from sales through veterinary clinics.

“Credelio Quattro continues to break boundaries when it comes to offering veterinarians and pet owners parasite protection,” Bobby Modi, executive vice president of U.S. Pet Health and Global Digital Transformation at Elanco, said in a written statement. “The introduction of Credelio Quattro has bolstered our broader Elanco portfolio in U.S. veterinary clinics, with Elanco now offering veterinarians a complete ecto, endo, and endecto portfolio with a variety of parasite coverage at a variety of price points to meet veterinarian and pet owner needs.”

The momentum comes as Elanco prepares to open its $200 million-plus corporate campus next month on the west side of downtown Indianapolis.

In August, Elanco reported second-quarter results that CEO Jeff Simmons called its best quarterly earnings since its 2018 spinoff from Eli Lilly and Co. Quarterly profit was $11 million, compared with a net loss of $50 million during the same quarter last year.

Elanco said Credelio Quattro joins Experior as Elanco’s second of six recently launched products to reach the blockbuster milestone of $100 million annual net sales. Experior is given to beef steers and heifers fed in confinement for slaughter to reduce ammonia gas emissions from the animal or its waste.

The company said it is preparing to take Credelio Quattro global, with regulatory submissions in Australia, Canada, the European Union, the United Kingdom and Japan, setting up product expansion in 2026.

Also Monday, Elanco said Zenrelia—a dermatology treatment for dogs to relieve itchy and irritated skin—gained approval last month from the United Kingdom’s Veterinary Medicines Directorate.

Zenrelia is now available in the EU, U.K., Brazil, Canada, Japan and the United States, the company said.

“We are very pleased with the results we are seeing in the global market, with more than half a million dogs treated with Zenrelia,” Ramiro Cabral, executive vice president of Elanco International, said in a written statement.